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Abstract 
Atrophy and fatty infiltration are important causes of muscle weakness in inclusion body myositis (IBM). Muscle weakness can also be 
caused by reduced specific force; i.e. the amount of force generated per unit of residual muscle tissue. This study investigates in vivo specific 
force of the quadriceps and ex vivo specific force of single muscle fibers in patients with IBM. We included 8 participants with IBM and 
12 healthy controls, who all underwent quantitative muscle testing, quantitative MRI of the quadriceps and paired muscle biopsies of the 
quadriceps and tibialis anterior. Single muscle fibers were isolated to measure muscle fiber specific force and contractile properties. Both 
in vivo quadriceps specific force and ex vivo muscle fiber specific force were reduced. Muscle fiber dysfunction was accompanied by reduced 
active stiffness, which reflects a decrease in the number of attached actin-myosin cross-bridges during activation. Myosin concentration was 
reduced in IBM fibers. Because reduced specific force contributes to muscle weakness in patients with IBM, therapeutic strategies that 
augment muscle fiber strength may provide benefit to patients with IBM. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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1. Introduction 
Sporadic inclusion body myositis (IBM) is one of the most 
common acquired muscle disorders in adults over 50 years old 
[1,2] . Progressive disease is characterized by atrophy and fatty 
infiltration of muscle tissue, resulting in muscle weakness 
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[3–5] . In early disease, the quadriceps, deep finger flexors 
and the pharyngeal muscles are most frequently affected, 
restricting functional ability and quality of life [6–8] . IBM is 
the result of a complex and only partially understood interplay 
between muscle inflammation, degeneration and impaired 
proteostasis which results in the accumulation of proteins in 
rimmed vacuoles [9] . 
No curative treatment options are currently available for 
IBM. The use of bimagrumab, a myostatin inhibitor which 
aims to ameliorate muscle atrophy by promoting muscle 
growth, resulted in increased thigh muscle volume in a 
small proof of concept trial [10] . However, a subsequent 
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double-blind placebo controlled trial did not meet its primary 
endpoint [data not yet published]. A conference abstract on 
rapamycin treatment reported reduced fatty replacement and 
increased contractile cross-sectional area, but detected no 
change in quadriceps muscle strength [11] . This suggests that 
merely increasing the amount of muscle tissue is not sufficient 
to increase muscle strength in patients with IBM. 
Besides loss of muscle mass due to atrophy and fatty 
infiltration, muscle weakness can also be caused by a 
reduction in specific force, i.e. the amount of force generated 
per unit of residual muscle tissue. An important contributor to 
in vivo specific force is muscle fiber strength. In IBM, muscle 
fiber strength may potentially be affected by inflammation, 
which may trigger and sustain cell stress, resulting in 
sarcomeric protein degradation, accumulation of unwanted 
proteins and irreversible muscle fiber damage [12–14] . 
This study investigates in vivo specific force of the 
quadriceps and ex vivo specific force of single muscle fibers 
to determine whether muscle fiber dysfunction contributes 
muscle weakness in patients with IBM. 
2. Patients and methods 
2.1. Participants 
Patients with IBM fulfilling the 2010 modified Griggs 
criteria were recruited from the Radboud university medical 
center [15] . Healthy individuals without a history of 
neuromuscular disease were recruited as controls. Exclusion 
criteria for all participants were: age < 18 or ≥65 
years, diabetes mellitus, chronic obstructive pulmonary 
disease, chronic heart failure, current malignancy, previous 
treatment with chemotherapy and/or radiation therapy, use 
of corticosteroids during more than two weeks in the past 
5 years, current use of statins, being wheelchair bound, 
contra-indications for MRI or muscle biopsy. Participants 
were age-matched on the group level. All participants 
underwent a neurologic examination and creatine kinase (CK) 
was measured. In IBM patients anti-cN-1A reactivity was 
established using ELISA [16] . The Medical Ethics Review 
Committee region Arnhem-Nijmegen approved this study 
(no. 2011/181). Informed consent was obtained from each 
participant. 
2.2. Quantitative force studies 
Maximum voluntary contraction (MVC) of the quadriceps 
was measured with a custom-built setup as described 
previously [17] . The right leg was examined, except in 
the presence of asymmetrical muscle weakness as measured 
by MRC score in which case the weakest leg was tested. 
Subsequent imaging and muscle biopsy were performed in 
the same leg. MVC was measured with the hip angle at 90 °
and the knee angle set at 120 ° Participants were strapped at 
the hips and upper body to prevent compensatory movements. 
Participants were asked to perform a MVC of the quadriceps 
during 3s. Mean force from 3 contractions was used to 
represent MVC [18] . 
2.3. Quantitative muscle imaging 
Transversal T1 weighted, multi-echo T2 and Turbo 
Inversion Recovery Magnitude (TIRM) images of the upper 
and lower leg were acquired on a 3 Tesla MRI system 
(Tim TRIO, Siemens, Erlangen, Germany). Upper leg MRI 
images were obtained at 1/3 of the distance between anterior 
superior iliac spine and patella, this level also corresponded 
to the approximate site of vastus lateralis muscle biopsy. 
Lower leg images were obtained at the level that corresponded 
to the approximate site of the tibialis anterior muscle 
biopsy. Muscle fraction and fat fraction were quantified 
from the multi-echo T2 images [19] . Total muscle cross- 
sectional area (TCSA) was determined by manually tracing 
the outline of the quadriceps using ImageJ. The amount of 
fatty infiltration (FCSA) was determined by multiplying the 
fat fraction with the TCSA. Residual quadriceps contractile 
cross-sectional area (CCSA) was determined by multiplying 
the muscle fraction with the TSCA. In vivo specific force was 
calculated by dividing the quadriceps MVC by the quadriceps 
CCSA. 
2.4. Muscle biopsies 
A needle biopsy of both the vastus lateralis and of the 
tibialis anterior was obtained. The vastus lateralis – part 
of the quadriceps – was chosen because this muscle is 
involved early and severely in patients with IBM. The tibialis 
anterior was included to obtain additional tissue from a less 
severely affected muscle in the lower limb. Biopsy specimens 
were snap-frozen in isopentane and stored at −80 °C for 
histological analysis and deposited in a solution containing 
half glycerol and half relaxing solution and stored at −20 °C 
for single fiber studies (the composition of this solution is 
described elsewhere [20] ). 
2.5. Histopathological analysis 
Frozen sections underwent HPhlox and ATPase staining 
to evaluate fiber size and type distribution. HPhlox was 
used to evaluate variability in fiber size, extent of central 
nucleation, necrosis and regeneration, interstitial fibrosis and 
inflammation. Severity was graded as normal (0), mild (1), 
moderate (2) or severe (3) for each of these parameters and 
scores were added to provide a cumulative histopathological 
severity score [21] . Inflammation was graded separately. 
All histopathology and inflammation severity scores were 
assigned by an experienced neuropathologist who was not 
aware whether a biopsy belonged to the control or IBM 
group. Morphometric analysis was performed to establish 
the percentages of each fiber type by a final-year pathology 
resident and randomly checked by an experienced pathology 
analist. 
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2.6. Single muscle fiber studies 
2.6.1. Muscle fiber preparation 
Biopsy material was placed in a relaxing solution 
containing 1% Triton X-100 and kept at 4 °C during 
isolation of single muscle fibers [22] . Triton permeabilizes the 
plasma membranes, resulting in ‘skinned’ muscle fibers. This 
procedure permits studies of sarcomeric function. Protease 
inhibitors were added to the solution to prevent protein 
degradation. Skinned single muscle fibers were isolated and 
fiber ends were attached to aluminum t-clips. The clips were 
mounted between a length motor on one end, and a force 
transducer on the other. Sarcomere length was set at 2.5 μm 
for measurement of maximum force, cross-bridge cycling 
kinetics, and calcium sensitivity. After adjusting sarcomere 
length, fiber length and cross-sectional area were measured. 
2.6.2. Muscle fiber specific force and contractile properties 
We determined the maximum force generation by 
activating the fibers with a saturating Ca 2 + solution (pCa 
4.5). Specific force was determined by dividing the generated 
maximum force by the fiber cross-sectional area, thus 
reflecting the force generated by the sarcomeres. After 
peak force was reached, a rapid unloaded shortening and 
restretching of the muscle fiber was used to determine the 
rate constant of force redevelopment (ktr). Ktr depends on the 
attachment and detachment rate of actin-myosin cross-bridges 
during activation, and thereby reflects the fraction of strongly 
bound cross-bridges . After peak force is reached a second 
time, slight length perturbations ( −0.9, −0.6, −0.3, 0.3, 0.6 
and 0.9%) are imposed on the muscle fiber to determine 
the active stiffness, which is dependent on the number of 
attached cross-bridges during activation . The tension/stiffness 
ratio reflects the amount of force generated per cross-bridge 
(assuming the myofibrils are intact). 
After measurement of maximum force and cross-bridge 
cycling kinetics, the fiber is rested for 5 min and sarcomere 
length is verified and adjusted if necessary. Next, calcium 
sensitivity of force generation was measured by transfer of 
the muscle fiber to solutions with increasing concentrations 
of Ca 2 + . Force-pCa data were fitted to the Hill equation to 
provide the pCa 50 , which is the pCa at which 50% of maximal 
active tension is reached. 
2.6.3. Muscle fiber protein analysis 
After contractile experiments, individual fibers were stored 
in 25 μl of SDS sample buffer until MHC isoforms analysis. 
MHC isoform composition and concentration of isolated 
single fibers was determined using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis(SDS-PAGE) [17] . Sample 
volumes of 8 μl were loaded per lane. Gels were run for 24 h 
at 15 °C and a constant voltage of 275 V. The composition 
of the sample buffer and stacking gel is described elsewhere 
[23] . In hybrid fibers (9% of fibers in both the control and 
IBM group), fiber type was assigned as type 1 or type 2 based 
on the predominant MHC isoform. Because there were only a 
limited amount of type 2X fibers ( N = 5) these were analyzed 
together with type 2A fibers. 
2.7. Statistics 
Statistical analysis was performed with IBM SPSS 
Statistics 22. We used sex as a covariate where appropriate 
to account for the overrepresentation of men in the IBM 
group. Continuous data were analyzed using independent 
samples t -test. Ordinal data were analyzed using Pearson 
Chi-square. Single fiber measurements were analyzed with 
linear mixed models. A random intercept was modeled for 
individual biopsies and individual subjects, using a “Variance 
components” covariance structure. Data are mean ± standard 
error of the mean (SEM) unless otherwise specified. 
2.8. Data availability 
A study protocol has been published previously [17] . 
Anonymized data are available on request. 
3. Results 
3.1. Participants and biopsies 
We included 8 IBM patients aged 49–64 years (7M/1F) 
and 12 healthy control subjects aged 42–65 years (6M/6F). 
Two IBM patients fulfilled the 2010 modified Griggs criteria 
for pathologically defined IBM, four fulfilled the criteria for 
clinically defined IBM, and one patient fulfilled the criteria 
for possible IBM. We were unable to find enough female 
IBM patients that fulfilled the inclusion criteria, which is why 
a higher number of female controls participated. To account 
for the overrepresentation of men in the IBM group we used 
sex as a covariate in appropriate statistical analyses. Muscle 
biopsies of both the vastus lateralis and tibialis anterior 
were obtained from all participants, except in two. In one 
IBM participant, advanced fatty infiltration prohibited vastus 
lateralis muscle biopsy. Another IBM participant declined a 
muscle biopsy of the tibialis anterior. For each muscle biopsy, 
8–20 single muscle fibers were measured (median 12 fibers 
per biopsy). We measured a total of 299 control muscle fibers 
(type 1 muscle fiber: 50.2%, type 2 muscle fiber: 49.8%) 
and 189 IBM muscle fibers (type 1: 69.8, type 2: 30.2%). 
Additional information about participants, laboratory findings 
and muscle biopsy characteristics is provided in Table 1 . 
3.2. In vivo quadriceps specific force 
3.2.1. Quantitative force studies 
Quadriceps MVC was significantly decreased in IBM 
patients (MVC: 217 ± 58 N in IBM vs. 572 ± 53 N in 
controls, p < .001, Fig. 1 A). 
3.2.2. Quantitative muscle MRI 
To determine the amount of atrophy and fatty infiltration 
we determined the TCSA and FCSA relative to control 
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Fig. 1. Quadriceps muscle strength . A. Maximum voluntary contractile force of the quadriceps is reduced in IBM patients compared to healthy controls. 
B. Reduced TCSA, indicating muscle atrophy, and increased FCSA, indicating fatty replacement of muscle tissue, in IBM patients result in a reduced amount 
of available contractile tissue, or CCSA. Stars indicate p -value for TCSA (line above bars), FCSA (within bar chart), and CCSA (within bar chart). C. Specific 
force is significantly reduced in IBM patients compared to healthy controls. D. Upper leg MRI for a control and IBM participant. Individual muscles of the 
quadriceps are indicated in the control image. Participant C4, right leg: TCSA 98%, FCSA 4%, CCSA 94%. Participant I2, left leg: TCSA 65%, FCSA 31%, 
CCSA 34%. 
Abbreviations: CCSA = contractile cross-sectional area. IBM = inclusion body myositis. MVC = maximum voluntary contraction. RF = rectus femoris. 
VI = vastus intermedius. VM = vastus medialis. VL = vastus lateralis. p < .05 is considered significant, ∗ p < .05, ∗∗ p < .01, ∗∗∗ p < .001. 
muscles ( Fig. 1 B). TCSA was reduced by 28% in IBM 
patients (TCSA: 72.3 ±5.9% in IBM vs. 100 ± 2.5% in 
controls, p = .002, Fig. 1 B). Of the remaining muscle tissue, 
33% was replaced by fat (FCSA: 32.9 ±6.5% in IBM vs. 
7.7 ±2.0% in controls, p = .005, Fig. 1 B). As a result of 
atrophy and fatty replacement of muscle tissue, CCSA was 
reduced by 53% in IBM patients (CCSA: 39.4 ±10% in IBM 
vs. 92.3 ±2.4% in controls, p = .001, Fig. 1 B). 
3.2.3. Quadriceps specific force 
We calculated in vivo quadriceps specific force (MVC 
/ CCSA) to determine whether reduced contractile quality 
of remaining muscle tissue also contributed to quadriceps 
muscle weakness. There was a linear relationship between 
quadriceps MVC and CCSA ( r 2 = 0.832, p < .001, Fig. 1 C). 
Specific force was reduced in IBM patients compared to 
control individuals, which indicates dysfunction of residual 
muscle tissue ( p = .003). 
3.3. Ex vivo single muscle fiber studies 
3.3.1. Vastus lateralis single muscle fiber specific force 
We isolated single muscle fibers from vastus lateralis 
muscle biopsies to determine whether reduced in vivo 
quadriceps specific force was caused by reduced muscle fiber 
specific force ( Fig. 2 A). Single muscle fiber specific force was 
reduced in IBM (type 1 specific force: 151.4 ±5.9 mN/mm 2 
in IBM vs. 181.9 ±4.4 mN/mm 2 in controls; type 2 specific 
force: 179.5 ±7.9 mN/mm 2 in IBM vs. 215.3 ±6.7 mN/mm 2 
in controls, p = .003, Fig. 2 B). 
3.3.2. Vastus lateralis single muscle fiber contractile 
properties 
In permeabilized single muscle fibers, specific force 
depends largely on (1) the fraction of strongly bound actin- 
myosin cross-bridges, (2) the number of available cross- 
bridges, and (3) the force per cross-bridge [24,25] . Reduced 
force generation should be accompanied by a change in one 
or more of these parameters. 
The rate constant of force redevelopment (ktr) represents 
cross-bridge attachment and detachment rates during 
activation and provides information on the fraction of strongly 
bound cross-bridges. Ktr was not decreased in IBM muscle 
fibers (type 1 Ktr: 5.9 ±0.9 s − 1 in IBM vs. 4.9 ±0.3 s − 1 
in controls, p = .380; type 2 Ktr: 12.6 ±0.8 s − 1 in IBM vs. 
13.2 ±0.5 s − 1 in controls, p = .743, Fig. 2 C). 
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Fig. 2. Reduced specific force and altered actin-myosin interactions in vastus lateralis single muscle fibers. A. Representative force tracing showing transfer 
of the muscle fiber to a saturating Ca 2 + solution, followed by generation of force. After peak force is reached, a rapid unloaded shortening and restretching 
of the muscle fiber is used to determine the Ktr, which is an estimate of the attachment and detachment rate of actin-myosin cross-bridges during activation. 
After peak force is reached a second time, slight length perturbations ( −0.3, −0.6, −0.9, 0.3, 0.6 and 0.9%) are imposed on the muscle fiber to determine the 
active stiffness, which is an estimate of the number of attached cross-bridges during activation. B. Specific force is reduced in vastus lateralis IBM muscle 
fibers. C. Ktr is not changed in IBM fibers, reflecting preserved attachment and detachment rate of actin-myosin cross-bridges during activation. D. Active 
stiffness is reduced in IBM fibers, indicating a reduced number of cross-bridges during activation. E. No reduction in the tension / stiffness ratio, reflecting 
preserved force generated per cross-bridge. p < .05 is considered significant, ∗ p < .05, ∗∗ p < .01, ∗∗∗ p < .001. 
Active stiffness, which reflects the number of attached 
cross-bridges during activation, was reduced in IBM 
fibers of both fiber types (type 1 active stiffness: 
69.6 ±4.5 mN/mm 2 / L in IBM vs. 89.6 ±3.4 mN/mm 2 / L 
in controls; type 2 active stiffness: 64.3 ±3.8 mN/mm 2 / L 
in IBM vs. 79.3 ±2.6 mN/mm 2 / L in controls, p = .015, 
Fig. 2 D). 
Assuming a situation in which all myofibrils within a 
muscle fiber are intact, the tension/stiffness ratio represents 
the amount of force generated per cross-bridge. The 
tension/stiffness ratio was not different in IBM patients (type 
1 tension/stiffness ratio: 2.4 ±0.2 in IBM vs. 2.2 ±0.1 in 
controls; type 2 tension/stiffness ratio: 3.1 ±0.1 in IBM vs. 
2.95 ± 0.1 in controls, p = .300, Fig. 2 E). 
To summarize, our results indicate that reduced specific 
force in IBM fibers is caused by a decrease in the number of 
attached actin-myosin cross-bridges during activation. 
3.3.3. Tibialis anterior single muscle fiber specific force 
Specific force in single muscle fibers obtained from 
tibialis anterior biopsies was lower in IBM, but not 
significantly different from control fibers (type 1 specific 
force: 162.1 ±5.4 mN/mm 2 in IBM vs. 175.1 ±5.5 mN/mm 2 
Fig. 3. Correlation between single fiber specific force and quadriceps 
strength. Ex vivo single muscle fiber specific force correlates with in vivo 
quadriceps quantitative strength. 
in controls; type 2 specific force: 182.8 ±17.8 mN/mm 2 in 
IBM vs. 212.0 ±5.3 mN/mm 2 in controls, p = .195). 
3.3.4. Correlation with disease severity 
Vastus lateralis single muscle fiber specific force correlated 
reasonably well with in vivo quadriceps strength ( p = .018, 
Fig. 3 ). We found no significant correlation with disease 
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Table 1 
Participants and muscle biopsy characteristics. 
Control IBM p 
Participants 
N 12 8 –
Age (years) 53.8 ±1.7 58.5 ±1.8 .081 
Sex 6 M/6F 7 M/1F .085 
BMI (cm/m 2 ) 27.3 ±1.5 26.6 ±1.6 .752 
Disease duration (years) N/A 6.4 ±1.3 –
IBM criteria 
Pathologically defined N/A 2 –
Clinically defined N/A 4 –
Possible N/A 1 –
Laboratory findings 
CK (U/L) 158 ± 41 772 ± 261 .045 
cN-1A reactivity (N) N/A 2/8 –
Muscle and biopsy characteristics 
Vastus lateralis 
MRC score (quadriceps) 5.0 ±0.0 4.0 ±0.9 .005 
MRI 
Fatty infiltration (%) 8.3 ±2.5 51.6 ±12.1 .009 
Inflammation or edema (N) 0/12 3/8 .021 
Histopathology 
Histopathology severity score 1.0 ±1.0 7.0 ±6.0 .021 
Inflammation score 0.0 ±0.0 2.0 ±0.3 < 0.001 
Fiber type distribution (type 1%) 57.6 ±4.0 57.7 ±9.1 .997 
Tibialis anterior 
MRC score 5.0 ±0.0 4.5 ±0.8 .005 
MRI 
Fatty infiltration (%) 3.9 ±0.8 29.6 ±10.2 .006 
Inflammation or edema (N) 0/12 2/8 .068 
Histopathology 
Histopathology severity score 2.0 ±1.0 6.0 ±6.0 .037 
Inflammation score 0.0 ±0.0 2.0 ±1.0 .005 
Fiber type distribution (type 1%) 68.3 ±20.5 76.9 ±5.2 .343 
Data are reported as mean ± SEM for continuous data, and median ± IQR 
for ordinal data. 
Abbreviations: CK: creatinine kinase. IBM: inclusion body myositis. MRC: 
Medical Research Council. 
duration ( p = .159), MRI fat percentage ( p = .548) or 
histopathology severity score ( p = .476). 
3.3.5. Calcium sensitivity 
To investigate other potential causes of muscle fiber 
weakness we evaluated calcium sensitivity of force generation 
( Fig. 3 A). The pCa 50 , which represents the calcium 
concentration at which 50% of maximum force is reached, 
did not differ between affected IBM and control fibers (type 1 
pCa 50 : 5.82 ± 0.01 in IBM vs. 5.77 ± 0.01 in controls; type 
2 pCa 50 : 5.82 ± 0.02 in IBM vs. 5.79 ± 0.01 in controls, 
p = .073). The Hill coefficient, a measure of myofilament 
cooperativity, was also unchanged in IBM fibers (type 1 n H : 
2.9 ±0.1 in IBM vs. 3.0 ±0.1 in controls; type 2 n H : 3.5 ±0.1 
in IBM vs. 3.6 ±0.1 in controls, p = .845) ( Fig. 4 ). These 
results indicate that the amount of force generated in response 
to a specific calcium concentration does not differ between 
fibers of IBM patients and healthy controls. 
3.3.6. Myosin heavy chain concentration 
Reduced single muscle fiber specific force due to a 
decreased number of attached cross-bridges during activation 
Fig. 4. Calcium sensitivity of force in IBM muscle fibers. A. Representative 
force tracing showing transfer of the muscle fiber to solutions with increasing 
concentrations of Ca 2 + , resulting in incremental force generation. After peak 
force is reached at a saturating Ca 2 + solution (pCa 4.5) the fiber is transferred 
to a relaxing solution. B. Specific force-pCa curve for type 1 and type 2 
fibers. There is no difference in pCa 50 , the pCa at which 50% of maximum 
force is reached, between groups. 
may be caused by impaired actin-myosin interactions or 
myosin loss. After force studies, MHC concentration was 
determined in a subset of single muscle fibers ( N = 90). 
Myosin concentration was significantly reduced in IBM type 
1 fibers (type 1: 63.3 ±5.7 μg/ μl in IBM vs. 106.6 ±8.2 in 
controls μg/ μl, p = .034) ( Fig. 5 ). Myosin concentration was 
also reduced in type 2 fibers, however this finding failed to 
reach significance, most likely due to the low number of 
type 2 fibers ( N = 6) that was encountered due to type 1 
predominance in the IBM fibers (type 2: 61.84 ± 12.3 in 
IBM vs. 84.4 ±4.85 in controls, p = .108). 
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Fig. 5. Single muscle fiber MHC concentration. Single muscle fiber MHC 
concentration is reduced in IBM type 1 fibers. A reduction is also present 
in type 2 fibers, however this failed to reach significance probably due to a 
lower number of type 2 fibers in this subset. 
4. Discussion 
Atrophy and fatty infiltration of the quadriceps are 
hallmark features of IBM and reduce the amount of muscle 
tissue available for contraction, resulting in quadriceps muscle 
weakness. This study demonstrates that quadriceps strength in 
patients with IBM is further decreased due to reduced specific 
force. An important contributor to in vivo specific force is 
muscle fiber strength, which is reduced by 17% due to a 
decreased number of attached cross-bridges during activation, 
suggesting myosin loss or impaired actin-myosin interaction. 
A previous study on contractile function in IBM muscle 
fibers obtained from biceps and vastus lateralis has previously 
reported preserved contractile function [26] . However, this 
study included a small number of patients ( N = 5 biopsies, 
N = 115 IBM fibers) with relatively short disease duration (1–
5 years). IBM is a progressive disease and biopsies obtained 
at an early stage may fail to show characteristic muscle 
abnormalities [27] . Our cohort included more patients and 
a longer disease duration of 2–10 years ( N = 14 biopsies, 
N = 236 IBM fibers). Discrepancies between our results and 
the previous study may also be related to confounding factors 
such as age, lifestyle and comorbid disease that are difficult 
to control for in human studies. Advanced cell models, 
for example skeletal muscle-on-a-chip platforms that allow 
contractile studies in terminally differentiated striated muscle 
fibers, may complement studies that used patient-derived 
muscle tissue. 
We observed that muscle fiber specific force was reduced 
in vastus lateralis, but not in tibialis anterior. In IBM, the 
quadriceps is affected early in the disease course. This 
was reflected in the current study: the quadriceps had 
a lower MRC grade, more severe fatty infiltration and 
higher histopathology sumscores compared to tibialis anterior. 
Furthermore, ex vivo vastus lateralis single muscle fiber 
specific force correlated with in vivo quadriceps quantitative 
strength. These findings suggest that reduced muscle fiber 
specific force in IBM is a consequence of progressive disease. 
We found no correlation between single muscle fiber specific 
force and disease duration or fatty infiltration, most likely 
because rates of disease progression may differ significantly 
between IBM patients, and because extensive inflammation 
may be present in biopsies from clinically and radiologically 
spared muscles [28,29] . 
In single muscle fiber preparations, the plasma membranes 
are eliminated using a ‘skinning’ solution which enables 
the study of sarcomeric function without the confounding 
influence of endomysial connective tissue, membranous 
structures and endoplasmatic reticulum calcium handling. As 
a consequence, reduced single muscle fiber specific force 
reflects dysfunction of the sarcomere. The mechanisms that 
result in sarcomeric weakness may be disease specific and 
include loss of structural proteins and impaired interaction 
between sarcomeric proteins [30] . A potential cause of 
reduced muscle fiber specific force as seen in our patient with 
IBM is myosin loss. 
Myosin concentration was indeed reduced in IBM muscle 
fibers in this study. Due to myosin loss, less actin- 
myosins crossbridges can be formed resulting in muscle 
fiber weakness. Reduced muscle fiber specific force due to 
myosin loss is also observed in patients with ICU-acquired 
weakness, and in these patients is caused by upregulation of 
the ubiquitin-proteasome pathway [31] . Some studies have 
suggested that this pathway is also disrupted in IBM [32] . 
Sustained cell stress due to inflammation may also result 
in sarcomeric protein degradation and muscle fiber damage 
[12–14] . Loss of sarcomeric proteins has been reported in 
IBM, with more severe depletion of type 2 structural proteins 
including myosin heavy chain [33] . 
Reduced muscle fiber specific force due to impaired 
actin-myosin interaction has also been reported in nemaline 
myopathy due to mutations in NEB , ACTA1 , TPM2 and TPM3 
[34] . Mutations in these genes all induce structural changes 
in sarcomeric proteins that are components of the actin-based 
thin filament, resulting in contractile abnormalities due to 
impaired actin-myosin interaction. Whole exome sequencing 
study found no abnormalities in nemaline myopathy-related 
genes in 30 Finnish IBM patients [35] . However, we can’t 
exclude the possibility that IBM and nemaline myopathy 
share common pathways in the development of muscle 
weakness. 
Studies on single muscle fiber contractile function 
in other muscle disorders are limited. Reduced single 
muscle fiber specific force was reported in small studies 
including muscle biopsies from patients with Duchenne 
muscular dystrophy ( N = 4), myotonic dystrophy ( N = 2) 
and facioscapulohumeral muscular dystrophy ( N = 4) 
[36–38] . This suggests that reduced muscle fiber specific 
force may be a general consequence of muscle disease. 
However, these studies are small and our experience in 
larger datasets of muscle fibers from facioscapulohumeral 
( N = 28) and oculopharyngeal muscular dystrophy ( N = 23) 
muscle biopsies is that progressive muscle pathology is not 
generally associated with reduced muscle fiber specific force 
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(unpublished data). Furthermore, muscle degeneration in 
mobility-limited older adults was not associated with reduced 
single muscle fiber specific force [39] . 
Recent therapeutic trials in IBM resulted in an increased 
amount of muscle mass, but did not improve functional 
performance or quadriceps strength [10,11] . Reduced specific 
force due to muscle fiber dysfunction may explain why merely 
promoting muscle growth or reducing fatty infiltration may 
not result in clinical improvement. Therapeutic strategies 
that augment muscle fiber contractile strength may provide 
benefit to patients with IBM, either alone or combined with 
therapeutic agents that increase or preserve muscle mass. Our 
findings also underline the importance of functional outcome 
measures, as muscle imaging will not reflect all components 
of muscle weakness. 
We included a relatively small number of IBM patients 
and were unable to include enough women that fulfilled 
the inclusion criteria. Hence, we used sex as a covariate 
in statistical analysis where appropriate to account for the 
overrepresentation of men in the IBM group. There were no 
significant differences between men and women. 
Quadriceps muscle strength was assessed by voluntary 
muscle contraction, which is influenced by pain, fatigue or 
lack of motivation. However, we do not expect these factors 
to have negatively influenced voluntary force generation in 
IBM participants. Five out of eight IBM patients reported no 
pain, and experimental protocols included resting periods to 
negate the influence of fatigue. 
Skinned single muscle fiber preparations are, by design, 
limited to evaluation of the contractile apparatus of the 
muscle fiber. Hence, our experiments do not address upstream 
mechanisms of force generation such as sarcoplasmic 
reticulum Ca 2 + handling or mitochondrial abnormalities, 
which require intact muscle fibers that cannot be obtained 
from routine muscle biopsies. 
5. Conclusions 
Specific force is reduced in IBM single muscle fibers and 
contributes to in vivo reduced specific force of the quadriceps. 
Muscle fiber weakness is caused by a decreased number of 
actin-myosin cross-bridges during activation, which is caused 
by myosin loss. Therapeutic strategies that augment muscle 
fiber strength may provide benefit to patients with IBM. 
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